Erasca, Inc. · NASDAQ:ERAS

Erasca — EORTC-NCI-AACR (ENA) Symposium 2026

16 slides from Erasca's conference presentation, November 2026

  1. Slide 1: Preliminary Safety, Pharmacokinetics, and Efficacy of ERAS-0015: Results From the AURORAS-1 First-in-human Trial

    Preliminary Safety, Pharmacokinetics, and Efficacy of ERAS-0015: Results From the AURORAS-1 First-in-human Trial Judy S. Wang, MD,1 Alexander Spira, MD, PhD, FASCO,2 Yonina R. Murciano-Goroff, MD, DPhil, MSc, MS,3 Erminia Massarelli, MD, PhD, MS,4 Ignacio Garrido-Laguna, MD, PhD,5 Harshabad Singh, M

  2. Slide 2: Author Disclosures

    Author Disclosures Judy S. Wang Consulting or Advisory Role: NGM Biopharmaceuticals; Kapadi CRO Research Funding: Accent Therapeutics; Abdera Therapeutics; Acrivon Therapeutics; Alterome Therapeutics; Angiex; ArriVent Biopharma; Astellas Pharma; Avacta Life Sciences; Avenzo Therapeutics; BeiGene; Bi

  3. Slide 3: Introduction

    Introduction ERAS-0015 inhibits RAS signaling through two mechanisms • RAS GTPases are key to the RAS/MAPK pathway, and are pivotal in tumor cell proliferation and survival1-3 RAS-GTP RAS-GDP ERAS-0015 Inactive State Active State 2 • Oncogenic mutations that shift RAS from a GDP- to GTP-bound (RAS-O

  4. Slide 4: Study Design and Patient Disposition

    AURORAS-1: Study Design and Patient Disposition ERAS-0015 Monotherapy in Solid Tumors Part 1: Dose Escalationa Part 1: Expansion Patient Disposition Key Eligibility Criteria Oral QD PDAC Patients treated 3-week cycles (N=148)b • Adults with locally advanced or metastatic: 40 mg MAD PDAC NSCLC 32 mg

  5. Slide 5: Demographics and Baseline Disease Characteristics

    AURORAS-1: Demographics and Baseline Disease Characteristics Total (N=148) Age, median (range), years 65.0 (36–88) Female, n (%) 62 (41.9) Patients With PDAC (N=83) Patients With NSCLC (N=37) KRAS Mutation Type KRAS Mutation Type ECOG PS 1, n (%) 109 (73.6) Tumor type, n (%) PDAC 87 (58.8) NSCLC 38

  6. Slide 6: ERAS-0015 Exhibited Linear PK and Robust Reduction of KRAS G12X ctDNA

    AURORAS-1: ERAS-0015 Exhibited Linear PK and Robust Reduction of KRAS G12X ctDNA Mean PK Profiles Change in Solid Tumor ctDNA KRAS G12X VAF from C1D1 to C3D1 C1D1 C1D15 0 ERAS-0015 Whole Blood Concentration Change in KRAS G12X Variant Allele Fraction (%) From C1D1 to C3D1 Cohort 2 mg –25 100 100 4 m

  7. Slide 7: ERAS-0015 Was Safe and Generally Well Tolerated Across Pharmacologically Active Dose Range

    AURORAS-1: ERAS-0015 Was Safe and Generally Well Tolerated Across Pharmacologically Active Dose Range TRAEs in Patients Receiving ERAS-0015 16–32 mg (N=122) TRAEs in ≥10% of patients, n (%) Grade 1 Grade 2 Grade 3a Grade 4 Grade 5 All Grades Rashb 61 (50.0) 34 (27.9) 4 (3.3) 0 0 99 (81.1) Diarrhea 3

  8. Slide 8: ERAS-0015 Safety at 32 mg Was Similar to 16–32 mg Dose

    AURORAS-1: ERAS-0015 Safety at 32 mg Was Similar to 16–32 mg Dose TRAEs in Patients Receiving ERAS-0015 at PAD of 16–32 mg and at 32 mg 16–32 mg QD 32 mg QD TRAEs in ≥10% of patients (16-32 mg), n (%) (N=122) (N=54) Rasha 99 (81.1) 43 (79.6) Diarrhea 39 (32.0) 19 (35.2) Nausea 29 (23.8) 12 (22.2) St

  9. Slide 9: Tumor Reduction and Response in 2L+ KRAS G12X PDAC at 16–32 mg QD

    AURORAS-1: Tumor Reduction and Response in 2L+ KRAS G12X PDAC at 16–32 mg QD ERAS-0015 16–32 mg (N=60) 100 16 mg QD 80 24 mg QD Maximum % Change 32 mg QD 60 Treatment ongoing From Baseline 40 PD # Responses confirmed after data cutoff 20 SD PD SD SD SD SD SD SD SD PD SD 0 SD SD SD SD SD SD PD SD SD

  10. Slide 10: Tumor Reduction and Response in 2L+ KRAS G12X PDAC at 32 mg QD

    AURORAS-1: Tumor Reduction and Response in 2L+ KRAS G12X PDAC at 32 mg QD ERAS-0015 32 mg (N=25) 100 32 mg QD 80 ERAS-0015 Treatment ongoing Maximum % Change 60 # Responses confirmed after data cutoff From Baseline 40 20 SD PD SD SD SD SD SD 0 SD – 20 NE SD NE SD SD SD – 40 uPR uPR PR PR uPR uPR – 6

  11. Slide 11: Duration of Treatment in 2L+ KRAS G12X PDAC

    AURORAS-1: Duration of Treatment in 2L+ KRAS G12X PDAC KRAS G12X: ERAS-0015 16–32 mg (N=60) D SD D uPR V SD V PR D SD V SD R SD R SD D PR/uCR D PR V uPR # V SD D PD V SD R uPR R SD V PR D SD V SD SD • All responders except one D D SD V SD D PD R R V V SD SD SD SD patient remain on treatment D SD V S

  12. Slide 12: Tumor Reduction and Response in 2L+ KRAS G12X NSCLC at 16-32 mg QD

    AURORAS-1: Tumor Reduction and Response in 2L+ KRAS G12X NSCLC at 16-32 mg QD ERAS-0015 16–32 mg (N=24) 100 16 mg QD 80 24 mg QD Maximum % Change 32 mg QD 60 Treatment ongoing From Baseline PD 40 # Responses confirmed after data cutoff 20 SD 0 SD SD NE SD SD SD – 20 SD SD SD – 40 SD PR PR PR uPR PR

  13. Slide 13: Duration of Treatment in 2L+ KRAS G12X NSCLC

    AURORAS-1: Duration of Treatment in 2L+ KRAS G12X NSCLC ERAS-0015 16–32 mg (N=24) KRAS G12X: V PR R PR V PR F V PR PR • 10 out of 12 responders A NE remain on treatment A SD V SD including all responders at R V PR SD 24 and 32 mg doses V SD A PD A uPR # D SD 16 mg QD V PR 24 mg QD V PR 32 mg QD D PR

  14. Slide 14: Tumor Reduction, Response, and Duration of Treatment in KRAS G12X BTC

    AURORAS-1: Tumor Reduction, Response, and Duration of Treatment in KRAS G12X BTC ERAS-0015 2–32 mg (N=11) ERAS-0015 2–32 mg (N=11)a KRAS G12X: 100 2 mg QD 80 8 mg QD R SD Maximum % Change 16 mg QD 60 24 mg QD V PR From Baseline PD 32 mg QD 40 Treatment ongoing R SD 20 SD SD 0 D PD SD SD – 20 SD V SD

  15. Slide 15: Conclusions: AURORAS-1 Phase 1

    Conclusions: AURORAS-1 Phase 1 • ERAS-0015 exhibited linear PK across the dose range • Preliminary safety data from AURORAS-1 suggest ERAS-0015 was safe and generally well tolerated • ERAS-0015 was safe and generally well tolerated at pharmacologically active doses of 16–32 mg and at 32 mg with no o

  16. Slide 16: Acknowledgements

    Acknowledgements We would like to thank the patients, caregivers, investigators, and staff for their participation in the AURORAS-1 study.

Erasca — EORTC-NCI-AACR (ENA) Symposium 2026 on 6ix